<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>expectations &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/expectations/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Mon, 11 Nov 2024 21:55:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>expectations &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Novo Nordisk shares rise 8% after Wegovy sales beat expectations</title>
		<link>https://bloggingthree.soflytech.com/2024/11/novo-nordisk-shares-rise-8-after-wegovy-sales-beat-expectations/</link>
					<comments>https://bloggingthree.soflytech.com/2024/11/novo-nordisk-shares-rise-8-after-wegovy-sales-beat-expectations/#respond</comments>
		
		<dc:creator><![CDATA[enzo2go]]></dc:creator>
		<pubDate>Mon, 11 Nov 2024 21:55:55 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[beat]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[Nordisk]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[rise]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[Wegovy]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=18963</guid>

					<description><![CDATA[Novo Nordisk on Wednesday reported a third-quarter sales increase for its blockbuster weight-loss drug Wegovy and lowered its full-year 2024 growth forecast. The company&#39;s shares jumped early Wednesday and were last up 7.7% at 9:02 a.m. London time. The Danish pharmaceutical giant said its third-quarter net profit reached 27.3 billion Danish kroner ($3.92 billion), above [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Novo Nordisk on Wednesday reported a third-quarter sales increase for its blockbuster weight-loss drug Wegovy and lowered its full-year 2024 growth forecast.</p>
<p>The company&#39;s shares jumped early Wednesday and were last up 7.7% at 9:02 a.m. London time.</p>
<p>The Danish pharmaceutical giant said its third-quarter net profit reached 27.3 billion Danish kroner ($3.92 billion), above the general LSEG estimate of 26.95 billion Danish kroner.</p>
<p>Novo Nordisk added that Wegovy&#39;s third-quarter sales rose 79% year-on-year and amounted to 17.3 billion Danish crowns. This was above the 15.9 billion Danish crowns that analysts had expected, in accordance with a consensus prepared by the corporate, Reuters reported.</p>
<p>The company narrowed its full-year 2024 revenue growth forecast to 23% to 27% from 22% to twenty-eight% at constant exchange rates and tightened its operating profit growth forecast to 21% to 27%, up from the previously expected 20% to twenty-eight%, each at constant exchange rates.</p>
<p>The forecast reflected the corporate&#39;s expectations for sales growth in North America and internationally, driven largely by volume growth of glucagon-like peptide-1 (GLP-1)-based treatments, Novo Nordisk said.</p>
<p>“Following unexpectedly high volume growth in recent years, including GLP-1 based products such as Ozempic and Wegovy, coupled with the expectation of continued volume growth and capacity constraints at some manufacturing sites, the outlook also reflects expected continued regular supply constraints and related Drug shortage reports for a range of products and regions,” she added.</p>
<p>Novo Nordisk added that it&#8217;s investing in capability each internally and externally to extend supply within the short and long run.</p>
<p>Regionally, Novo Nordisk&#39;s revenue in North America increased 22% yr over yr within the third quarter of 2024. Sales in the important thing US market rose 21% within the period, with GLP-1 volumes within the region increasing 15%.</p>
<p>“Novo Nordisk is the market leader with 53.9% in terms of total monthly prescriptions and 50.0% in terms of new brand prescriptions,” the corporate said.</p>
<p>The health titan has faced increasing competition, but has also received promising news in the burden loss space in recent months.</p>
<p>Last week, the U.S. Food and Drug Administration said all doses of Wegovy were now available within the U.S., after previously noting that the bottom dose of Wegovy was briefly supply. The news was seen as a signal that Novo Nordisk&#39;s efforts to extend supplies of Wegovy and diabetes drug Ozempic are paying off.</p>
<p>Also in October, a study showed that Ozempic may reduce the danger of developing Alzheimer&#39;s disease, suggesting it could delay or prevent the memory-robbing condition.</p>
</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
					<wfw:commentRss>https://bloggingthree.soflytech.com/2024/11/novo-nordisk-shares-rise-8-after-wegovy-sales-beat-expectations/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<media:content url="https://i1.wp.com/image.cnbcfm.com/api/v1/image/107384064-1709830398609-gettyimages-1830849279-porzycki-ozempicp231207_npYtz.jpeg" medium="image"></media:content>
				</item>
		<item>
		<title>Scientists world wide report thousands and thousands of latest discoveries yearly &#8211; but this explosive research growth has not met experts&#039; expectations</title>
		<link>https://bloggingthree.soflytech.com/2024/10/scientists-world-wide-report-thousands-and-thousands-of-latest-discoveries-yearly-but-this-explosive-research-growth-has-not-met-experts-expectations/</link>
					<comments>https://bloggingthree.soflytech.com/2024/10/scientists-world-wide-report-thousands-and-thousands-of-latest-discoveries-yearly-but-this-explosive-research-growth-has-not-met-experts-expectations/#respond</comments>
		
		<dc:creator><![CDATA[enzo2go]]></dc:creator>
		<pubDate>Tue, 15 Oct 2024 06:11:10 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[discoveries]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experts39]]></category>
		<category><![CDATA[explosive]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Met]]></category>
		<category><![CDATA[millions]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[scientists]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[year]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=17338</guid>

					<description><![CDATA[Millions of scientific papers are published worldwide yearly. These essays from the fields of science, technology, engineering, mathematics, and medicine present discoveries that range from the mundane to the profound. It has been since 1900 Number of published scientific articles has doubled roughly every 10 to fifteen years; since 1980 around 8 to 9% annually. [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div itemprop="articleBody">
<p><a href="https://ncses.nsf.gov/pubs/nsb202333/publication-output-by-region-country-or-economy-and-by-scientific-field">Millions of scientific papers</a> are published worldwide yearly. These essays from the fields of science, technology, engineering, mathematics, and medicine present discoveries that range from the mundane to the profound. </p>
<p>It has been since 1900 <a href="https://doi.org/10.1007/s11192-010-0202-z">Number of published scientific articles</a> has doubled roughly every 10 to fifteen years; <a href="https://asistdl.onlinelibrary.wiley.com/doi/10.1002/asi.23329">since 1980 around 8 to 9% annually</a>. This acceleration reflects the immense and <a href="https://www.science.org/doi/10.1126/science.aao0185">constantly growing research spectrum</a> on countless topics, from the farthest corners of the cosmos to the intricacies of life on Earth and human nature. </p>
<figure class="align-right zoomable">
<div class="placeholder-container" style="--aspect-ratio-percent:143.03797468354432%;--background-color:#344956"><img decoding="async" alt="Derek de Solla Price wears glasses and sits in a chair with a metal device." class="lazyload" src="https://images.theconversation.com/files/622870/original/file-20241001-16-tqa7mg.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=237&#038;fit=clip" srcset="https://images.theconversation.com/files/622870/original/file-20241001-16-tqa7mg.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=600&#038;h=858&#038;fit=crop&#038;dpr=1 600w, https://images.theconversation.com/files/622870/original/file-20241001-16-tqa7mg.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=600&#038;h=858&#038;fit=crop&#038;dpr=2 1200w, https://images.theconversation.com/files/622870/original/file-20241001-16-tqa7mg.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=600&#038;h=858&#038;fit=crop&#038;dpr=3 1800w, https://images.theconversation.com/files/622870/original/file-20241001-16-tqa7mg.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;h=1078&#038;fit=crop&#038;dpr=1 754w, https://images.theconversation.com/files/622870/original/file-20241001-16-tqa7mg.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=754&#038;h=1078&#038;fit=crop&#038;dpr=2 1508w, https://images.theconversation.com/files/622870/original/file-20241001-16-tqa7mg.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=754&#038;h=1078&#038;fit=crop&#038;dpr=3 2262w" sizes="(min-width: 1466px) 754px, (max-width: 599px) 100vw, (min-width: 600px) 600px, 237px"></div><figcaption>
              <span class="caption">Derek de Solla Price has written an influential book concerning the growth rate of science.</span><br />
              <span class="attribution"><a class="source" href="https://en.wikipedia.org/wiki/Derek_J._de_Solla_Price#/media/File:DerekdeSollaPrice.jpg">The de Solla Price family/Wikimedia Commons</a></span><br />
            </figcaption></figure>
<p>But this extraordinary expansion was once considered unsustainable. In his <a href="https://philpapers.org/rec/PRILSB">influential book from 1963</a>“Little Science, Big Science… And Beyond”, the founding father of scientometry – or <a href="https://www.sciencedirect.com/topics/social-sciences/scientometrics">Data informatics in reference to scientific publications</a> – <a href="https://scholar.google.com/citations?user=Ev26B2YAAAAJ&#038;hl=en">Derek de Solla Price</a> As is well-known, limits to scientific growth were predicted. </p>
<p>He warned that the world&#39;s resources and talent pool for research would soon be exhausted. He imagined that this may result in a decline in latest discoveries and possible crises in medicine, technology and economics. At the time, <a href="https://doi.org/10.1515/9781503639102">Scholars widely accepted</a> his prediction of an impending slowdown in scientific progress. </p>
<h2>False predictions</h2>
<p>In fact, science has spectacularly contradicted Price&#39;s dire prediction. Instead of stagnation, the world is now experiencing “<a href="https://doi.org/10.1515/9781503639102">global megascience</a>” – an unlimited, ever-expanding network of scientific discoveries. This explosion in scientific production made Price&#39;s prediction of a collapse perhaps probably the most stunningly false prediction within the science of science. </p>
<p>Unfortunately, Price died in 1983, too soon to comprehend his mistake. </p>
<p>So what explains the world&#39;s continued and dramatically growing capability for scientific research? </p>
<p><a href="https://scholar.google.com/citations?user=rZsAGT4AAAAJ&#038;hl=en">We are sociologists</a> WHO <a href="https://scholar.google.de/citations?user=PiwNMGkAAAAJ&#038;hl=en">Studying higher education and natural sciences</a>. Our latest book &#8220;<a href="https://doi.org/10.1515/9781503639102">Global mega-science: universities, research collaborations and knowledge production</a>&#8220;, published on the sixtieth anniversary of Price&#39;s fateful prediction, offers explanations for this rapid and sustained scientific growth. It traces the history of scientific discoveries worldwide.</p>
<p>Factors equivalent to economic growth, warfare, the space race, and geopolitical competition have undoubtedly boosted research capability. But these aspects alone cannot explain the immense scale of today&#39;s scientific endeavors.</p>
<h2>The Education Revolution: The Secret Engine of Science</h2>
<p>In some ways, the world&#39;s scientific capability relies on the academic aspirations of young adults searching for higher education.</p>
<figure class="align-center zoomable">
<div class="placeholder-container" style="--aspect-ratio-percent:66.71087533156499%;--background-color:#4f372f"><img decoding="async" alt="University graduates wear graduation regalia." class="lazyload" src="https://images.theconversation.com/files/622871/original/file-20241001-16-aw952i.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;fit=clip" srcset="https://images.theconversation.com/files/622871/original/file-20241001-16-aw952i.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=600&#038;h=400&#038;fit=crop&#038;dpr=1 600w, https://images.theconversation.com/files/622871/original/file-20241001-16-aw952i.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=600&#038;h=400&#038;fit=crop&#038;dpr=2 1200w, https://images.theconversation.com/files/622871/original/file-20241001-16-aw952i.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=600&#038;h=400&#038;fit=crop&#038;dpr=3 1800w, https://images.theconversation.com/files/622871/original/file-20241001-16-aw952i.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;h=503&#038;fit=crop&#038;dpr=1 754w, https://images.theconversation.com/files/622871/original/file-20241001-16-aw952i.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=754&#038;h=503&#038;fit=crop&#038;dpr=2 1508w, https://images.theconversation.com/files/622871/original/file-20241001-16-aw952i.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=754&#038;h=503&#038;fit=crop&#038;dpr=3 2262w" sizes="(min-width: 1466px) 754px, (max-width: 599px) 100vw, (min-width: 600px) 600px, 237px"></div><figcaption>
              <span class="caption">Funds from higher education support much of the fashionable scientific enterprise.</span><br />
              <span class="attribution"><a class="source" href="https://newsroom.ap.org/detail/MichiganCommencement/488cce2cae4b4e058b0ba716b5090b1b/photo?Query=college%20graduates&#038;mediaType=photo&#038;sortBy=&#038;dateRange=Anytime&#038;totalCount=5&#038;digitizationType=Digitized&#038;currentItemNo=0&#038;vs=true">AP Photo/Paul Sancya</a></span><br />
            </figcaption></figure>
<p>Over the last 125 years, increasing demand for and access to higher education has sparked a world education revolution. <a href="https://ourworldindata.org/grapher/gross-enrollment-ratio-in-tertiary-education?time=earliest..2022">More than two-fifths of young people worldwide at the moment are between 19 and 23 years old</a>are enrolled at universities, albeit with large regional differences. This revolution is the engine of scientific research capability. </p>
<p><a href="https://www.whed.net/home.php">Today there are greater than 38,000 universities and other higher education institutions worldwide</a> play a vital role in scientific discovery. The education mission, funded each publicly and privately, subsidizes the research mission, with a big portion of scholars&#39; tuition fees going toward faculty support. </p>
<p>These faculty scholars mix their teaching with conducting extensive research. <a href="https://doi.org/10.1515/9781503639102">University scientists contribute 80 to 90%</a> of discoveries published in thousands and thousands of articles annually.</p>
<p><a href="https://www.oecd.org/en/data/datasets/main-science-and-technology-indicators.html">External research funding</a> remains to be essential for specialised equipment, supplies, and extra support for research time. But above all, the day by day research capability of universities <a href="https://doi.org/10.1093/scipol/scab010">Academics work in teams</a>forms the idea of world scientific progress.</p>
<p>Even probably the most generous national budgets for science and industrial research and development cannot fully cover the essential infrastructure and personnel required for ongoing scientific discovery. </p>
<p>Likewise, state laboratories and independent research institutes equivalent to the USA <a href="https://www.nih.gov/">National Institutes of Health</a> or Germany <a href="https://www.mpg.de/short-portrait">Max Planck Institutes</a>couldn&#8217;t replace production <a href="https://www.timeshighereducation.com/opinion/why-germany-not-embracing-humboldtian-university">Capacity that universities offer</a>.</p>
<h2>Science and society profit from collaboration</h2>
<p>The previous few a long time have also seen an upsurge in global scientific collaborations. These agreements leverage diverse talent from world wide to enhance the standard of research. </p>
<p>International collaborations have led to this <a href="https://doi.org/10.2478/jdis-2023-0015">Millions of co-authored articles</a>. International research partnerships were relatively rare before 1980; they accounted for just over 7,000 works, which was about 2% of world production that yr. However, by 2010 this number had increased to 440,000 papers, meaning that 22% of world scientific publications were the results of international collaborations. </p>
<p><iframe id="xodGg" class="tc-infographic-datawrapper" src="https://datawrapper.dwcdn.net/xodGg/1/" height="400px" width="100%" style="border: 0;" scrolling="no" frameborder="0"></iframe></p>
<p>This growth, built on the “cooperation dividend,” continues today and has proven to guide to success <a href="https://doi.org/10.1007/s11192-024-05010-6">Research with the best impact</a>.</p>
<p>Universities are inclined to share academic goals with other universities and have extensive networks and a culture of openness, making this collaboration relatively easy. </p>
<p>Today, universities also play a key role in international super-collaborations involving teams of lots of and even hundreds of scientists. In these huge collaborations, researchers can answer necessary questions that they&#8217;d not have the opportunity to resolve in smaller groups with fewer resources. </p>
<p>Supercollaborations have enabled breakthroughs in understanding the complicated physics of the universe and synthesizing evolution and genetics that scientists in a single country could never achieve alone.</p>
<figure class="align-center zoomable">
<div class="placeholder-container" style="--aspect-ratio-percent:75.19893899204244%;--background-color:#293b51"><img decoding="async" alt="The IceCube Observatory, a small square building on the Antarctic ice, with symbols representing neutrinos streaming down from the sky." class="lazyload" src="https://images.theconversation.com/files/619670/original/file-20240916-20-c5x89l.png?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;fit=clip" srcset="https://images.theconversation.com/files/619670/original/file-20240916-20-c5x89l.png?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=600&#038;h=451&#038;fit=crop&#038;dpr=1 600w, https://images.theconversation.com/files/619670/original/file-20240916-20-c5x89l.png?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=600&#038;h=451&#038;fit=crop&#038;dpr=2 1200w, https://images.theconversation.com/files/619670/original/file-20240916-20-c5x89l.png?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=600&#038;h=451&#038;fit=crop&#038;dpr=3 1800w, https://images.theconversation.com/files/619670/original/file-20240916-20-c5x89l.png?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;h=567&#038;fit=crop&#038;dpr=1 754w, https://images.theconversation.com/files/619670/original/file-20240916-20-c5x89l.png?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=754&#038;h=567&#038;fit=crop&#038;dpr=2 1508w, https://images.theconversation.com/files/619670/original/file-20240916-20-c5x89l.png?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=754&#038;h=567&#038;fit=crop&#038;dpr=3 2262w" sizes="(min-width: 1466px) 754px, (max-width: 599px) 100vw, (min-width: 600px) 600px, 237px"></div><figcaption>
              <span class="caption">The IceCube collaboration, a major example of a world mega-collaboration, has made great strides in understanding neutrinos, that are ghostly particles from space that go through Earth.</span><br />
              <span class="attribution"><span class="source">Martin Wolf, IceCube/NSF</span></span><br />
            </figcaption></figure>
<h2>The role of world hubs</h2>
<p>Through the networking of universities world wide, scientific research has turn out to be thoroughly global. The first of those global hubs, consisting of dozens of North American research universities, emerged within the Seventies. In the Eighties they expanded into Europe and most recently Southeast Asia. </p>
<p>This <a href="https://www.aau.edu/newsroom/press-releases/global-research-intensive-universities-issue-joint-call-collaboration">regional centers and alliances of universities</a> connect scientists from lots of of universities to pursue joint research projects.</p>
<p>Scientists at these universities often crossed geopolitical boundaries: Iranian researchers published papers with Americans, Germans collaborated with Russians and Ukrainians, and Chinese scientists collaborated with their Japanese and Korean colleagues. </p>
<p>The COVID-19 pandemic has clearly demonstrated the immense extent of international collaboration in global megascience. Within just six months of the beginning of the pandemic, scientists world wide had already published papers <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov">23,000 scientific studies on the virus</a>. These studies contributed to the rapid development of effective vaccines. </p>
<p>The growing global networks of universities mean that collaborations can spread to all parts of the world via necessary research centers.</p>
<h2>Is global megascience sustainable?</h2>
<p>Yet despite the impressive growth of scientific production, this kind of highly collaborative and transnational megascience faces challenges. </p>
<p>On the one hand, birth rates are falling in lots of countries where lots of science is produced. On the opposite hand, many youth world wide, particularly in low-income countries, have less access to higher education. <a href="https://higheredstrategy.com/world-higher-education-institutions-students-and-funding">although there was some recent progress within the Global South</a>. </p>
<p>Sustaining these global collaborations and this high level of scientific achievement means expanding access to higher education. This is because higher education funds subsidize research costs, and better education trains the following generation of scientists.</p>
<p>De Solla Price couldn&#8217;t have predicted how necessary universities could be in driving <a href="https://doi.org/10.1515/9781503639102">global science</a>. The way forward for scientific production depends, for higher or worse, on the longer term of those institutions.</p>
</p></div>
<p><em>image credit : theconversation.com</em></p>
]]></content:encoded>
					
					<wfw:commentRss>https://bloggingthree.soflytech.com/2024/10/scientists-world-wide-report-thousands-and-thousands-of-latest-discoveries-yearly-but-this-explosive-research-growth-has-not-met-experts-expectations/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<media:content url="https://i3.wp.com/images.theconversation.com/files/619684/original/file-20240916-16-55hgzd.jpg" medium="image"></media:content>
				</item>
		<item>
		<title>Luck influences voting behavior – and the present mood in America could confuse the expectations of young and old voters</title>
		<link>https://bloggingthree.soflytech.com/2024/09/luck-influences-voting-behavior-and-the-present-mood-in-america-could-confuse-the-expectations-of-young-and-old-voters/</link>
					<comments>https://bloggingthree.soflytech.com/2024/09/luck-influences-voting-behavior-and-the-present-mood-in-america-could-confuse-the-expectations-of-young-and-old-voters/#respond</comments>
		
		<dc:creator><![CDATA[enzo2go]]></dc:creator>
		<pubDate>Tue, 17 Sep 2024 16:15:22 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[confuse]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[influences]]></category>
		<category><![CDATA[luck]]></category>
		<category><![CDATA[mood]]></category>
		<category><![CDATA[voters]]></category>
		<category><![CDATA[voting]]></category>
		<category><![CDATA[young]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=14993</guid>

					<description><![CDATA[Luck could reshape America&#39;s political landscape. Since the Nineteen Sixties and the election of President John F. Kennedy, younger voters have supported Democratic candidates while older voters have tended to support Republicans. But This dynamic has evolvedand today, in 2024, large parts of each groups defy traditional assumptions about their political affiliation. This shift challenges [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div itemprop="articleBody">
<p>Luck could reshape America&#39;s political landscape. </p>
<p>Since the Nineteen Sixties and the election of President John F. Kennedy, younger voters have supported Democratic candidates while older voters have tended to support Republicans. But <a href="https://www.cnn.com/2024/06/15/politics/election-age-what-matters/index.html">This dynamic has evolved</a>and today, in 2024, large parts of each groups defy traditional assumptions about their political affiliation.</p>
<p>This shift challenges the age-old political adage that youthful idealism gives approach to conservative pragmatism with age. As pollsters and pundits struggle to clarify the phenomenon, an intriguing theory is emerging: It might be <a href="https://worldhappiness.report/ed/2024/">come all the way down to happiness</a>.</p>
<h2>The dissatisfied vote for change</h2>
<p>I&#8217;m a <a href="https://scholar.google.com/citations?user=J9oQu2AAAAAJ&#038;hl=en">Researcher in interpersonal communication</a> and co-founder and co-director of <a href="https://www.faupolling.com/">Mainstreet Laboratory for Political Communication at Florida Atlantic University</a>. Our lab studies and analyzes public opinion and political trends across the country. With the election approaching, I actually have been particularly studying the potential influence of luck on voting behavior.</p>
<p>Worldwide research shows that glad people prefer to go away things as they&#8217;re. <a href="https://worldhappiness.report/ed/2019/happiness-and-voting-behavior/">are inclined to vote for the incumbent in political elections</a>Voters who&#8217;re less glad usually tend to support anti-establishment candidates because they see the federal government as a source of their dissatisfaction. </p>
<p>These results may help explain the Democratic Party&#39;s declining support amongst young people. </p>
<p>This group remains to be reliably blue. Vice President Kamala Harris <a href="https://www.nbcnews.com/politics/2024-election/poll-half-gen-z-voters-support-kamala-harris-one-third-back-donald-tru-rcna169025">has a lead amongst voters under 30</a>with 50% preferring her to 34% of former President Donald Trump. US voters aged 18 to 35 mainly prefer Democratic views on <a href="https://www.pewresearch.org/religion/fact-sheet/public-opinion-on-abortion/">Issues reminiscent of abortion</a> And <a href="https://thehill.com/changing-america/respect/equality/3531837-generation-z-extremely-concerned-about-lgbtq-rights-survey-says/">LGBTQ+ rights</a>. Nevertheless, they&#8217;re voting for the Republicans more often than up to now. <a href="https://www.nbcnews.com/politics/2024-election/poll-half-gen-z-voters-support-kamala-harris-one-third-back-donald-tru-rcna169025">especially young men</a>. </p>
<h2>Youth isn&#8217;t any longer carefree</h2>
<p>Declining life satisfaction and happiness levels amongst young Americans could also be one reason for his or her changing political preferences.</p>
<p>Our <a href="https://www.faupolling.com/march-19-2024/">Survey from March 2024</a> found that 55% of respondents aged 18 to 34 were dissatisfied with their lives, in comparison with 65% of the overall population. </p>
<p>These findings, <a href="https://www.scientificamerican.com/article/young-adulthood-is-no-longer-one-of-lifes-happiest-times/">and other national surveys</a>challenge the widespread belief that young maturity is one in every of the happiest periods of life.</p>
<p><iframe id="W4fTL" class="tc-infographic-datawrapper" src="https://datawrapper.dwcdn.net/W4fTL/5/" height="400px" width="100%" style="border: 0;" scrolling="no" frameborder="0"></iframe></p>
<p>Happiness is traditionally represented as a U-shaped curve, with the youngest and oldest voters reporting the best levels of happiness. <a href="https://www.scientificamerican.com/article/young-adulthood-is-no-longer-one-of-lifes-happiest-times/">Young adults worldwide</a> Most reported feeling carefree and glad, having fun with their newfound independence and opportunities. Older people had finally left the stress of balancing work, family and relationships behind and were starting to enjoy their retirement. </p>
<p>Today’s young Americans are unhappier than previous generations. This is true worldwide, in accordance with <a href="https://worldhappiness.report/ed/2024/happiness-and-age-summary/">World Happiness Report 2024</a>however the decline is especially dramatic within the US, where the suicide rate amongst young people increased <a href="https://www.cdc.gov/nchs/products/databriefs/db471.htm">over 60% between 2007 and 2021</a>. </p>
<p>Experts lead the <a href="https://www.cnbc.com/2024/08/28/young-adults-are-unhappy-than-ever-but-dont-just-blame-social-media.html">Dissatisfaction amongst young Americans today is on account of countless aspects</a>including a childhood interrupted by the pandemic, the dramatic increase in <a href="https://k12ssdb.org/all-shootings">School shootings</a> and rising living costs. Young individuals are also stressed by political polarization, distrust of the media and the 2 wars in Ukraine and Gaza.</p>
<p>Social media reinforces these fears by encouraging young people to match themselves to others in unhealthy ways and exposing them to loads of negative news, which <a href="https://doi.org/10.1016/j.addbeh.2021.106949">make reality seem worse than it&#8217;s</a>. </p>
<p>All of those happiness-reducing concerns could influence political preferences. Some dissatisfied young voters are drawn to candidates who promise economic stability and growth. Other young adults who&#8217;re dissatisfied with the political system want radical change &#8211; any change. </p>
<h2>Seniors for Harris</h2>
<p>The changing political preferences of unhappy young Americans are particularly revealing in comparison to those of older Americans who&#8217;ve grow to be happier in recent times. </p>
<p><iframe id="YdXo8" class="tc-infographic-datawrapper" src="https://datawrapper.dwcdn.net/YdXo8/5/" height="400px" width="100%" style="border: 0;" scrolling="no" frameborder="0"></iframe></p>
<p><a href="https://www.newsweek.com/kamala-harris-polls-election-senior-vote-1948282">Current survey data</a> suggests that older voters, who&#8217;ve long been the Republican base, are trending toward Democrats in 2024. In September 2024, Harris leads amongst older voters, with between 51% and 55% preferring her to Trump. </p>
<p>These glad seniors seem concerned in regards to the profound changes that might occur under a brand new Trump administration, reminiscent of <a href="https://www.washingtonpost.com/politics/2024/09/04/democrats-campaign-2025/">End much more abortion rights</a>The Supreme Court&#39;s overturning of Roe v. Wade in 2022 undid what was considered a serious milestone and achievement of this generation. </p>
<p>Older Americans also value the preservation <a href="https://www.cnbc.com/2024/06/20/older-voters-want-candidates-who-will-protect-social-security.html">Social security advantages</a>a Democratic priority that Trump has strayed from, and maintaining lower prescription drug costs. Both programs help keep older Americans glad and healthy. They have little relevance for young people.</p>
<p>Polls are notoriously unreliable and continuously changing, but age is increasingly not a great indicator of party affiliation. </p>
<h2>Luck is vital on the ballot box</h2>
<p>I&#39;m not saying that luck determines all voting behavior or explains the changing political preferences within the United States. But I&#8217;m saying that it shouldn&#39;t be ignored. </p>
<figure class="align-center zoomable">
<div class="placeholder-container" style="--aspect-ratio-percent:64.9867374005305%;--background-color:#2c344d"><img decoding="async" alt="Democratic presidential candidate Vice President Kamala Harris and her running mate Governor Tim Walz smile broadly on stage." class="lazyload" src="https://images.theconversation.com/files/617927/original/file-20240906-16-g3heut.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;fit=clip" srcset="https://images.theconversation.com/files/617927/original/file-20240906-16-g3heut.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=600&#038;h=390&#038;fit=crop&#038;dpr=1 600w, https://images.theconversation.com/files/617927/original/file-20240906-16-g3heut.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=600&#038;h=390&#038;fit=crop&#038;dpr=2 1200w, https://images.theconversation.com/files/617927/original/file-20240906-16-g3heut.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=600&#038;h=390&#038;fit=crop&#038;dpr=3 1800w, https://images.theconversation.com/files/617927/original/file-20240906-16-g3heut.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;h=490&#038;fit=crop&#038;dpr=1 754w, https://images.theconversation.com/files/617927/original/file-20240906-16-g3heut.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=754&#038;h=490&#038;fit=crop&#038;dpr=2 1508w, https://images.theconversation.com/files/617927/original/file-20240906-16-g3heut.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=754&#038;h=490&#038;fit=crop&#038;dpr=3 2262w" sizes="(min-width: 1466px) 754px, (max-width: 599px) 100vw, (min-width: 600px) 600px, 237px"></div><figcaption>
              <span class="caption">Kamala Harris and Tim Walz have made “joy” a theme of their campaign, and the 2 candidates at all times had a smile on their faces through the campaign – including here in Philadelphia on August 6, 2024.</span><br />
              <span class="attribution"><a class="source" href="https://newsroom.ap.org/detail/Election2024JoyandGloom/8ebec7a024f5435aac5fc9766b8b62d3/photo?Query=(datelinelocation.countryname:%22united%20states%22)%20AND%20%20(kamala%20harris%20joy)%20&#038;mediaType=photo&#038;sortBy=arrivaldatetime:asc&#038;dateRange=Anytime&#038;totalCount=6&#038;currentItemNo=4">AP Photo/Matt Rourke, File</a></span><br />
            </figcaption></figure>
<p>My research shows that to grasp why people vote the best way they do, it is crucial to look at happiness alongside other key aspects reminiscent of the economy and private experiences. By examining how happiness is said to age, life experience, and social media engagement, researchers can gain clearer insights into the changing voting behavior of each young and old voters. </p>
<p>The 2024 presidential candidates appear to have sensed this. Harris&#39; campaign is all about &#8220;joy&#8221; and <a href="https://time.com/7018346/kamala-harris-joy-campaign-benefits-essay/">Celebrating joy and community</a>The Trump team is adopting an angrier tone and a more complaining approach. </p>
<p>Ultimately, happiness is greater than only a mood. The literal pursuit of happiness can influence decisions on the ballot box just as much as ideology.</p>
<p><em>Editor&#39;s note: The chart on this story documenting young people&#39;s dissatisfaction has been updated to correct a typo. Fifty-five percent of respondents under age 35 reported some level of dissatisfaction with their lives, not satisfaction.</em></p>
</p></div>
<p><em>image credit : theconversation.com</em></p>
]]></content:encoded>
					
					<wfw:commentRss>https://bloggingthree.soflytech.com/2024/09/luck-influences-voting-behavior-and-the-present-mood-in-america-could-confuse-the-expectations-of-young-and-old-voters/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<media:content url="https://i2.wp.com/images.theconversation.com/files/617931/original/file-20240906-18-ggpqda.jpg" medium="image"></media:content>
				</item>
		<item>
		<title>Biogen beats expectations and raises forecast as Alzheimer&#039;s drug Leqembi and other latest products gain traction</title>
		<link>https://bloggingthree.soflytech.com/2024/08/biogen-beats-expectations-and-raises-forecast-as-alzheimers-drug-leqembi-and-other-latest-products-gain-traction/</link>
					<comments>https://bloggingthree.soflytech.com/2024/08/biogen-beats-expectations-and-raises-forecast-as-alzheimers-drug-leqembi-and-other-latest-products-gain-traction/#respond</comments>
		
		<dc:creator><![CDATA[enzo2go]]></dc:creator>
		<pubDate>Sun, 04 Aug 2024 14:26:54 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Alzheimer39s]]></category>
		<category><![CDATA[beats]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[forecast]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Leqembi]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[raises]]></category>
		<category><![CDATA[traction]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=10885</guid>

					<description><![CDATA[Biogen on Thursday reported Second-quarter earnings and revenue beat estimates and raised full-year guidance as the corporate&#39;s cost-cutting efforts showed progress and sales of its breakthrough Alzheimer&#39;s drug Leqembi and other latest products exceeded expectations. Biogen now expects full-year adjusted earnings of $15.75 to $16.25 per share. The previous forecast was $15 to $16 per [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Biogen<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    on Thursday <a href="https://investors.biogen.com/news-releases/news-release-details/biogen-reports-second-quarter-2024-results" target="_blank" rel="noopener">reported</a> Second-quarter earnings and revenue beat estimates and raised full-year guidance as the corporate&#39;s cost-cutting efforts showed progress and sales of its breakthrough Alzheimer&#39;s drug Leqembi and other latest products exceeded expectations. </p>
<p>Biogen now expects full-year adjusted earnings of $15.75 to $16.25 per share. The previous forecast was $15 to $16 per share.</p>
<p>The biotech company also expects a low single-digit percentage decline in sales for 2024. Biogen&#39;s previous forecast assumed a low to mid single-digit percentage decline in comparison with the previous 12 months. </p>
<p>Leqembi, which Biogen shares with Eisai, became the second drug shown to slow the progression of Alzheimer&#39;s disease to be approved within the U.S. last summer. The therapy has been slow to roll out because of bottlenecks in requirements for diagnostic tests and regular brain scans, amongst other things. </p>
<p>But demand for Leqembi appears to be increasing. Sales of around $40 million were generated within the quarter, which is higher than the $31 million expected by analysts, in line with StreetAccount estimates. </p>
<p>After its launch last 12 months, the drug generated sales of just $10 million. </p>
<p>Biogen didn&#8217;t disclose what number of patients are currently taking Leqembi. In May, the corporate said about 5,000 people were taking the drug.</p>
<p>Nevertheless, Leqembi faces hurdles in Europe, where a drug regulator has advised against approving the drug due to the risk of brain swelling and bleeding. Biogen was &#8220;quite surprised and quite stunned&#8221; by the choice and can seek a brand new review, said company boss Chris Viehbacher in a press conference on Thursday.</p>
<p>Biogen hopes Leqembi and other latest products will fuel growth as the corporate cuts costs and grapples with falling demand for its multiple sclerosis therapies, a few of which face competition from cheaper generics. </p>
<p>“I can say today that all product launches met or exceeded expectations,” he said.</p>
<p>According to Viehbacher, the corporate is on course to realize gross cost savings of roughly $1 billion and net cost savings of $800 million by the top of 2025.</p>
<p>Viehbacher added: &#8220;While our operating expenses have decreased significantly, we have been able to invest heavily in the launch of new products and in the research and development projects that we consider most important.&#8221;</p>
<p>Here&#39;s what Biogen reported for the second quarter, in comparison with Wall Street expectations, based on an LSEG analyst survey: </p>
<ul>
<li><strong>Earnings per share: </strong>$5.28 adjusted vs. $4.03 expected</li>
<li><strong>Revenue: </strong>$2.47 billion in comparison with expected $2.38 billion</li>
</ul>
<p>Biogen reported revenue of $2.47 billion for the quarter, roughly the identical because the previous 12 months.</p>
<p>The pharmaceutical company reported net income of $583.6 million, or $4 per share, within the second quarter. In the identical period last 12 months, net income was $591.6 million, or $4.07 per share. </p>
<p>Adjusted for one-time items, the corporate reported earnings of $5.28 per share. </p>
<p>In addition to Leqembi, investors are also closely watching other newly launched drugs, including Skyclarys, which was created from Biogen&#39;s acquisition of Reata Pharmaceuticals in July 2023. </p>
<p>The drug generated sales of $100 million within the second quarter. Analysts had expected the drug to herald $92.3 million within the quarter, in line with StreetAccount. </p>
<p>The US Food and Drug Administration gave Skyclarys the green light last 12 months, making it the primary approved drug for Friedreich&#39;s ataxia, a rare degenerative genetic disease that may affect walking and coordination in children as young as five. </p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">More health reports from CNBC</h2>
</div>
</div>
</div>
</div>
<div class="group">
<p>Viehbacher said Skyclarys&#39; launch goes &#8220;extremely well.&#8221; The company expects to launch the drug in 20 countries by the top of the 12 months, he added.</p>
<p>Zurzuvae, the primary pill to treat postnatal depression, posted second-quarter sales of $14.9 million. Analysts had only expected sales of $11 million, in line with StreetAccount estimates.</p>
<p>Biogen is releasing this pill jointly with Sage Therapeutics.</p>
<p>Meanwhile, Biogen&#39;s sales of multiple sclerosis treatments fell 5% to $1.15 billion within the second quarter as some products face competition from cheaper generics. </p>
<p>Nevertheless, a few of these drugs achieved higher sales than expected. </p>
<p>Tecfidera, for instance, posted second-quarter sales of $252.2 million, relatively unchanged from the identical period last 12 months. Analysts had expected the once-blockbuster drug to post quarterly sales of $233.3 million, in line with StreetAccount.</p>
</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-2">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these insights from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
					<wfw:commentRss>https://bloggingthree.soflytech.com/2024/08/biogen-beats-expectations-and-raises-forecast-as-alzheimers-drug-leqembi-and-other-latest-products-gain-traction/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<media:content url="https://i1.wp.com/image.cnbcfm.com/api/v1/image/107371253-17074363572021-12-01t015552z_1514391558_rc2a5r9skh07_rtrmadp_0_biogen-results.jpeg" medium="image"></media:content>
				</item>
		<item>
		<title>Merck beats earnings expectations and raises sales forecast as a result of strong demand for top drugs equivalent to Keytruda</title>
		<link>https://bloggingthree.soflytech.com/2024/07/merck-beats-earnings-expectations-and-raises-sales-forecast-as-a-result-of-strong-demand-for-top-drugs-equivalent-to-keytruda/</link>
					<comments>https://bloggingthree.soflytech.com/2024/07/merck-beats-earnings-expectations-and-raises-sales-forecast-as-a-result-of-strong-demand-for-top-drugs-equivalent-to-keytruda/#respond</comments>
		
		<dc:creator><![CDATA[enzo2go]]></dc:creator>
		<pubDate>Tue, 30 Jul 2024 13:56:35 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[beats]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[due]]></category>
		<category><![CDATA[earnings]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[forecast]]></category>
		<category><![CDATA[Keytruda]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[raises]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strong]]></category>
		<category><![CDATA[top]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=10401</guid>

					<description><![CDATA[Merck reported second-quarter revenue and adjusted profit on Tuesday that beat Wall Street expectations, reflecting strong sales of its hit cancer drug Keytruda, in addition to other treatments in its oncology and vaccines portfolio and a newly launched cardiovascular drug. The pharmaceutical giant also raised its full-year revenue forecast to $63.4 billion to $64.4 billion [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Merck<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    reported second-quarter revenue and adjusted profit on Tuesday that beat Wall Street expectations, reflecting strong sales of its hit cancer drug Keytruda, in addition to other treatments in its oncology and vaccines portfolio and a newly launched cardiovascular drug. </p>
<p>The pharmaceutical giant also raised its full-year revenue forecast to $63.4 billion to $64.4 billion as demand for key products, particularly cancer drugs, has increased. That&#39;s only barely higher than the $63.1 billion to $64.3 billion forecast the corporate gave in April. </p>
<p>Merck lowered its adjusted earnings forecast to a variety of $7.94 to $8.04 per share, from a previous forecast of $8.53 to $8.65 per share. This updated forecast takes under consideration one-time costs of 26 cents and 51 cents per share for the acquisitions of <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/" target="_blank" rel="noopener">Harpoon therapeutics</a> And <a href="https://www.merck.com/news/merck-completes-acquisition-of-eyebio/" target="_blank" rel="noopener">EyeBio</a>said Merck.</p>
<p>Nevertheless, the corporate&#39;s shares lost greater than 6 percent on Tuesday.</p>
<p>Here is what Merck is doing for the <a href="https://www.businesswire.com/news/home/20240730509685/en/Merck-Announces-Second-Quarter-2024-Financial-Results" target="_blank" rel="noopener">second quarter</a> in comparison with Wall Street expectations based on an analyst survey conducted by LSEG: </p>
<ul>
<li><strong>Earnings per share: </strong>USD 2.28 adjusted versus USD 2.15 expected</li>
<li><strong>Revenue:</strong> $16.11 billion in comparison with expected $15.84 billion</li>
</ul>
<p>The pharmaceutical company reported a net profit of $5.46 billion, or $2.14 per share, within the second quarter. In the identical period last 12 months, the corporate reported a net lack of $5.98 billion, or $2.35 per share. This also included costs related to the acquisition of Prometheus Biosciences.</p>
<p>Excluding acquisition and restructuring costs, the corporate earned $2.28 per share within the three-month period.</p>
<p>Merck reported sales of $16.11 billion for the quarter, up 7% from the identical period last 12 months. </p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">More health reports from CNBC</h2>
</div>
</div>
</div>
</div>
<div class="group">
<p>The results come at a time when Merck is preparing to offset losses from the expiration of the Keytruda patent in 2028 by signing some recent contracts and bringing key medicines to market. </p>
<p>These include Winrevair, a drug approved within the United States in March to treat a progressive and life-threatening lung disease. Some analysts estimate that global sales of Winrevair could reach $5 billion by 2030. </p>
<p>It also includes <a href="https://www.merck.com/news/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults/" target="_blank" rel="noopener">Capvaxiv</a>a vaccine to guard adults against <a href="https://www.cdc.gov/pneumococcal/causes/index.html" target="_blank" rel="noopener">a bacterium known</a> equivalent to pneumococci, which might cause <a href="https://ndc.services.cdc.gov/case-definitions/invasive-pneumococcal-disease-2017/" target="_blank" rel="noopener">serious illness</a> and lung infections. The vaccine was approved within the US last month. </p>
</div>
<h2 class="ArticleBody-subtitle"><a id="headline0"></a>Sales of pharmaceuticals exceed estimates</h2>
<div class="group">
<p>Merck&#39;s pharmaceutical division posted sales of $14.41 billion within the second quarter, 7 percent greater than in the identical period last 12 months. The division develops a big selection of medication for various disease areas. </p>
<p>The company&#39;s immunotherapy drug Keytruda generated sales of $7.27 billion within the quarter, up 16 percent from the identical period last 12 months. Analysts had expected sales of $7.12 billion for Keytruda, in line with estimates from StreetAccount. </p>
<p>The increase was as a result of increased use of Keytruda in early-stage cancer and powerful demand in metastatic cancer, which spreads to other parts of the body, the corporate&#39;s chief financial officer, Caroline Litchfield, said during a conference call on Tuesday.</p>
<p>Sales of Gardasil, a vaccine to forestall HPV cancer, probably the most common sexually transmitted infection within the United States, remained virtually unchanged. </p>
<p>Gardasil posted sales of $2.48 billion, up just 1% from the second quarter of 2023. Merck said growth was driven by higher prices within the U.S. but was held back by lower sales in China as a result of delivery timing. </p>
<p>“As soon as we know more, we will evaluate future deliveries to our partner and work to restore their inventory to more normal levels,” Litchfield said.</p>
<p>According to StreetAccount, segment results were barely below the $2.51 billion expected by analysts. </p>
</div>
<div class="group">
<p>Winrevair reported second-quarter sales of $70 million following its approval in March. Analysts had expected the drug to generate sales of $59.4 million. </p>
<p>Merck estimates that about 40 percent of Winrevair sales are for doses given to U.S. patients, with the remainder coming from distributors build up inventory of the drug, Litchfield said. She noted that greater than 1,000 patients began Winrevair within the second quarter, largely as a result of prescriptions filled in April and May.</p>
<p>Meanwhile, type 2 diabetes drug Januvia posted sales of $629 million, down 27 percent from the identical period last 12 months. Merck said the decline was mainly as a result of lower demand and lower prices for the drug, together with competition from generics in several countries. </p>
<p>Januvia is considered one of 10 drugs which might be the topic of ongoing Medicare price negotiations, a policy designed to make expensive drugs more cost-effective for seniors. Those price negotiations, a key provision of President Joe Biden&#39;s inflation-fighting bill, end in early August.</p>
<p>Sales of Merck&#39;s antiviral Covid pill Lagevrio also fell, by 46% to $110 million within the quarter, but that also beat analysts&#39; expectations of sales of $81.5 million, in line with StreetAccount.  </p>
<p>Merck&#39;s animal health division, which develops vaccines and medicines for dogs, cats and cattle, reported second-quarter sales of $1.48 billion, up 2 percent from the identical period last 12 months and barely lower than analysts surveyed by StreetAccount had expected.</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-2">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these insights from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
					<wfw:commentRss>https://bloggingthree.soflytech.com/2024/07/merck-beats-earnings-expectations-and-raises-sales-forecast-as-a-result-of-strong-demand-for-top-drugs-equivalent-to-keytruda/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<media:content url="https://i2.wp.com/image.cnbcfm.com/api/v1/image/106952946-1633495041348-gettyimages-1235705476-porzycki-merckcop211004_npyt4.jpeg" medium="image"></media:content>
				</item>
		<item>
		<title>What David Seymour&#039;s expectations could mean for the drug purchasing agency</title>
		<link>https://bloggingthree.soflytech.com/2024/07/what-david-seymours-expectations-could-mean-for-the-drug-purchasing-agency/</link>
					<comments>https://bloggingthree.soflytech.com/2024/07/what-david-seymours-expectations-could-mean-for-the-drug-purchasing-agency/#respond</comments>
		
		<dc:creator><![CDATA[enzo2go]]></dc:creator>
		<pubDate>Mon, 22 Jul 2024 22:29:56 +0000</pubDate>
				<category><![CDATA[Politics]]></category>
		<category><![CDATA[agency]]></category>
		<category><![CDATA[David]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[Seymour39s]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=9706</guid>

					<description><![CDATA[Deputy Health Minister David Seymour Letter of expectation Decision-making on the pharmaceutical agency Pharmac could fundamentally change the best way the organization makes decisions. Some of those changes could also make Pharmac&#39;s work tougher and its decisions less popular. The letter has received considerable attention because the Minister expects Pharmac to pay less attention to [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div itemprop="articleBody">
<p>Deputy Health Minister David Seymour <a href="https://pharmac.govt.nz/assets/Uploads/Letter-of-Expectations-2024-25.pdf">Letter of expectation</a> Decision-making on the pharmaceutical agency Pharmac could fundamentally change the best way the organization makes decisions. Some of those changes could also make Pharmac&#39;s work tougher and its decisions less popular.</p>
<p>The letter has received considerable attention because the Minister expects Pharmac to pay less attention to the embedding of Te Tiriti o Waitangi within the health sector. This has already resulted in <a href="https://www.1news.co.nz/2024/07/19/pharmac-director-quits-over-governments-treaty-directive/">Resignation of a director</a>. </p>
<p>But a few of Seymour&#39;s other expectations have received less scrutiny than they deserve. </p>
<p>Pharmac currently has a core job (his <a href="https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/operating-policies-and-procedures">Legal objective</a>): to attain the very best health outcomes throughout the resources provided. </p>
<p>In his letter, Seymour calls for a reform of the funding model to have in mind &#8220;positive fiscal impacts&#8221;. This would require a change to Pharmac&#39;s statutory objectives and will ultimately do more harm than good to some New Zealanders. </p>
<h2>Consideration of productivity</h2>
<p>Pharmac evaluates latest medicines based on their cost and the potential savings for the remainder of the healthcare system. These are then compared with the extra health advantages of the brand new medicine. </p>
<p>Currently, a drug is funded if it provides sufficient profit and the budget is obtainable. If the drug doesn&#8217;t provide sufficient profit or if Pharmac cannot currently afford it, it goes to their <a href="https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/prioritisation/priority-lists">Investment List Options</a>.</p>
<p>In his letter, Seymour called on Pharmac to be certain that:</p>
<blockquote>
<p>Updates its decision-making and evaluation models to contemplate the broader government-wide financial impact of funding or not funding a drug or medical device, and has tools to contemplate the broader societal impacts. </p>
</blockquote>
<p>Pharmac is asked to have in mind the impact of a drug on economic productivity. This implies that the assessment takes into consideration whether a drug helps people to proceed working because they don&#8217;t get sick, or whether it helps them to return to work after being sick. </p>
<p>Global, <a href="https://link.springer.com/article/10.1007/s40273-022-01221-y">60% of drug authorities</a> have in mind the broader effects of medicines to various degrees, but there is no such thing as a clear agreement on the very best approach. Some countries consider the prices and health consequences of caregivers or parents, while others consider the time they&#8217;re unable to work. </p>
<p>The time spent away from work – lost productivity – may be measured with a “<a href="https://ard.bmj.com/content/69/Suppl_1/i89">Friction costs</a>&#39; approach (which counts the hours not worked until one other employee takes over the work of a sick person) or a &#39;human capital&#39; approach (where the indirect costs are the time lost attributable to illness valued on the market wage). </p>
<p>However, there may be a risk that those that usually are not considered ‘productive’ and who&#8217;ve low-paying jobs might be deemed less vital for treatment. This could include older people, individuals with disabilities and their carers, individuals who may never work due to their illness, and folks who face discrimination within the workplace (<a href="https://www.publicservice.govt.nz/research-and-data/workforce-data-remunerationpay/workforce-data-pay-gaps">Women, Māori and Pasifika</a>For example).  </p>
<p>If the pharmaceutical industry is to take productivity into consideration, the federal government must recognise that this might exacerbate existing inequalities.</p>
<h2>Greater patient involvement</h2>
<p>A <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783693/pdf/40900_2020_Article_248.pdf">International study</a> published in 2021 Pharmac recognized for its <a href="https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-020-05152-2">open advisory practice</a> in developing his “<a href="https://pharmac.govt.nz/medicine-funding-and-supply/the-funding-process/policies-manuals-and-processes/factors-for-consideration">Factors to contemplate</a>&#8221; Model. </p>
<p>But in his letter of expectations, Seymour says he expects Pharmac to do more to involve patient groups and whānau within the decision-making process. </p>
<p>While this sounds positive, it could also result in greater involvement by the pharmaceutical industry. Many patient advocacy groups receive funding from industry organizations. A recently published <a href="https://journals.sagepub.com/doi/epub/10.1177/0020731418823376">Australian study</a> found that pharmaceutical firms had given AU$34 million to patient organisations over a four-year period, often at a time when the businesses&#39; drugs were being scrutinised for public reimbursement. </p>
<p>These kinds of conflicts of interest must be managed, especially in a rustic with a really lively <a href="https://www.stuff.co.nz/national/politics/301023149/newsable-new-zealand-has-very-active-lobbying-scene-academic-says">Lobbying sector</a> and few safety precautions, even with <a href="https://www.rnz.co.nz/news/lobbying/486670/lobbyists-in-new-zealand-enjoy-freedoms-unlike-most-other-nations-in-the-developed-world">highest levels of presidency</a>.</p>
<h2>Role separation</h2>
<p>Pharmac can also be asked to contemplate separating roles in valuation and procurement. According to the Minister:</p>
<blockquote>
<p>The organization could […] Benefit from a more functionally separated procurement process.</p>
</blockquote>
<p>By assuming each roles, Pharmac can negotiate more effectively with the pharmaceutical industry &#8211; a novel feature in New Zealand. Separating the roles potentially compromises Pharmac&#39;s ability to barter by limiting the use of data about value. </p>
<p>Currently, Pharmac actively manages the drug plan in its role as purchaser. They use numerous <a href="https://www.cambridge.org/core/journals/health-economics-policy-and-law/article/pricing-strategies-executive-committee-power-and-negotiation-leverage-in-new-zealands-containment-of-public-spending-on-pharmaceuticals/573321297A6970CBB89C325D181637D8">Price and negotiation strategies</a>.  </p>
<p>Many of the less cost-effective treatments are placed on the investment options list within the hope that a deal may be negotiated later. Pharmac negotiates deals to finance these barely less beneficial drugs by negotiating higher terms for other treatments. </p>
<p>This could, for instance, involve bundling products from the identical pharmaceutical company or negotiating a lower cost for a more widely used drug in an upcoming tender. </p>
<p>Separating assessment from procurement makes such deals unlikely to occur. This implies that Pharmac, given its limited budget, could have to say &#39;no&#39; to funding a selected item more often, and every of those decisions carries the danger of causing further problems for the federal government.</p>
<p>The a part of Pharmac (or another agency) that does the valuation could not ask whether a treatment is inexpensive. Instead, it could have to make a decision how much each healthy 12 months of life is value and factor that into its decision-making. </p>
<p>To accommodate this latest number, firms are increasing the costs of recent drugs, making even the cheaper drugs costlier and putting more pressure on limited pharmaceutical budgets.</p>
</p></div>
<p><em>image credit : theconversation.com</em></p>
]]></content:encoded>
					
					<wfw:commentRss>https://bloggingthree.soflytech.com/2024/07/what-david-seymours-expectations-could-mean-for-the-drug-purchasing-agency/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<media:content url="https://i0.wp.com/images.theconversation.com/files/608399/original/file-20240722-16-6g3kdi.jpg" medium="image"></media:content>
				</item>
		<item>
		<title>By not lip-syncing Amy Winehouse&#039;s songs, actress Marisa Abela faces unattainable expectations in &#8220;Back to Black.&#8221;</title>
		<link>https://bloggingthree.soflytech.com/2024/05/by-not-lip-syncing-amy-winehouses-songs-actress-marisa-abela-faces-unattainable-expectations-in-back-to-black/</link>
					<comments>https://bloggingthree.soflytech.com/2024/05/by-not-lip-syncing-amy-winehouses-songs-actress-marisa-abela-faces-unattainable-expectations-in-back-to-black/#respond</comments>
		
		<dc:creator><![CDATA[enzo2go]]></dc:creator>
		<pubDate>Thu, 16 May 2024 19:41:10 +0000</pubDate>
				<category><![CDATA[Arts]]></category>
		<category><![CDATA[Abela]]></category>
		<category><![CDATA[actress]]></category>
		<category><![CDATA[Amy]]></category>
		<category><![CDATA[black]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[faces]]></category>
		<category><![CDATA[impossible]]></category>
		<category><![CDATA[lipsyncing]]></category>
		<category><![CDATA[Marisa]]></category>
		<category><![CDATA[songs]]></category>
		<category><![CDATA[Winehouse39s]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=3659</guid>

					<description><![CDATA[Like Amy Winehouse: “Back to black&#8220;, the brand new biopic in regards to the late British singer, was no stranger to controversy. In the case of the film, there was strong disagreement over director Sam Taylor-Johnson&#39;s decision to have actress Marisa Abela sing to Winehouse&#39;s recordings somewhat than lip-sync her. Some viewers have praised Abela&#39;s [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div itemprop="articleBody">
<p>Like Amy Winehouse: “<a href="https://www.imdb.com/title/tt21261712/?ref_=nv_sr_srsg_0_tt_8_nm_0_q_back%2520to%2520black">Back to black</a>&#8220;, the brand new biopic in regards to the late British singer, was no stranger to controversy. </p>
<p>In the case of the film, there was strong disagreement over director Sam Taylor-Johnson&#39;s decision to have actress Marisa Abela sing to Winehouse&#39;s recordings somewhat than lip-sync her. </p>
<p>Some viewers have <a href="https://www.reddit.com/r/amywinehouse/comments/1944un6/comment/khgi550/?utm_source=share&#038;utm_medium=web3x&#038;utm_name=web3xcss&#038;utm_term=1&#038;utm_content=share_button">praised Abela&#39;s voice</a>.  Others complained that she sounds &#8220;<a href="https://www.reddit.com/r/Fauxmoi/comments/1bqbdpr/excruciating_new_clip_from_back_to_black_starring/">nothing like that</a>“Winehouse or asked why anyone would even try to imitate him <a href="https://www.reddit.com/r/amywinehouse/comments/1bozgr7/biopic_singing/">such a “unique” voice</a>.</p>
<p>As a musicologist, the <a href="https://global.oup.com/academic/product/multivocality-9780190621476?cc=us&#038;lang=en&#038;">studies voice and identity</a>I see two elements fueling this dissonance.</p>
<p>First, Winehouse&#39;s distinctive sound relied on her own mimicry skills: she drew from an extended history of predominantly black female singers.</p>
<p>Second, some viewers appear to want Abela&#39;s voice to be a duplicate of Winehouse&#39;s voice.  But as I learned <a href="https://books.google.com/books?hl=en&#038;lr=&#038;id=ctqUDwAAQBAJ&#038;oi=fnd&#038;pg=PA77&#038;dq=fluid+voices+meizel&#038;ots=88DJws1kCl&#038;sig=WtAU5zVHaa1v9nztp6VW4U5xXr8#v=onepage&#038;q=fluid%20voices%20meizel&#038;f=false">my research</a>The art of vocal imitation is less about perfect replication;  Rather, it&#8217;s most successful when performers mimic certain points of a singer&#39;s sound which might be easily recognizable to listeners.</p>
<figure>
<p><iframe title="Marisa Abela&#039;s singing in new Amy Winehouse movie gets brutal reviews" width="1170" height="658" src="https://www.youtube.com/embed/O0UvHG6yARQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></p><figcaption><span class="caption">Actress Marisa Abela sings a song by Amy Winehouse.</span></figcaption></figure>
<h2>Imitation and appropriation</h2>
<p>Wine House, <a href="https://www.nytimes.com/2011/07/24/arts/music/amy-winehouse-british-soul-singer-dies-at-27.html">who died in 2011</a> At the age of 27, she didn&#39;t bring a very recent sound to the world during her short profession. </p>
<p>The 2006 album Back to Black, a collaboration with Mark Ronson, was deliberately a retro work.  It followed Winehouse&#39;s 2003 debut album Frank and brought together vibrant sounds from soul, neo-soul, funk, jazz, blues and R&#038;B &#8211; genres all created by black musicians and communities.</p>
<p>Yale professor Daphne Brooks <a href="https://www.thenation.com/article/archive/amy-winehouse-and-black-art-appropriation/">argued</a> that Winehouse&#39;s style took its core elements from black singers. </p>
<p>In Winehouse&#39;s hoarse voice, Brooks heard Sarah Vaughan, Billie Holiday, Lauryn Hill and others.  </p>
<p>In the singer&#39;s turbulent private life, Brooks saw echoes of the blues women of the Nineteen Twenties and Nineteen Thirties <a href="https://www.namimt.org/news/mental-health-in-history-bessie-smith-the-emperess-of-the-blues-triumph-over-trauma">who&#8217;ve suffered from addiction and trauma</a>.</p>
<p>And in Winehouse&#39;s signature look – her &#8220;beehive, satin dresses and little black gloves&#8221; – Brooks saw the elegant, sophisticated girl groups of the Fifties and Sixties, equivalent to <a href="https://rockhall.com/inductees/shirelles/">the Shirelles</a>.</p>
<p>Brooks also saw parallels with Sophie Tucker, a white Jewish singer and comedian who rose to fame within the Nineteen Twenties and who, like Winehouse, made her profession borrowing from the performance variety of black singers. </p>
<p>Winehouse didn&#8217;t hide the incontrovertible fact that she paid homage to the music and musicians she admired.  She even alluded to the difficult cultural tensions her work raised. <a href="https://www.hotpress.com/music/day-2006-amy-winehouse-releases-hit-single-rehab-22792396">told Hot Press in 2007</a> that she was all for “the old Motown, The Shangri-Las, Ella Fitzgerald, Dinah Washington, Ray Charles.” </p>
<p>Still, her critics were outspoken in regards to the appropriation in The New Yorker&#39;s &#8220;Back to Black,&#8221; featuring Sasha Frere-Jones <a href="https://www.newyorker.com/magazine/2008/03/03/amys-circus">Comparison of Winehouse&#39;s singing</a>  to “a kind of blackface.” </p>
<p>Frere-Jones wondered if the title “Back to Black” needs to be “literal.”  Abela complicated the equation together with her added layer of impersonation: her Winehouse voice over Winehouse&#39;s own retro sound.</p>
<h2>Capturing the “essence” of a singer</h2>
<p>Representing a lost and treasured artist is difficult in other ways, too. </p>
<p>The actors are expected to do justice to the fans&#39; memories.  Lip syncing with the late celebrity&#39;s voice <a href="https://people.com/movies/is-naomi-ackie-singing-in-i-wanna-dance-with-somebody/">Naomi Ackie did it</a> within the Whitney Houston film &#8220;<a href="https://www.imdb.com/title/tt12193804/">I would like to bop with someone</a>“can avoid the problem entirely.  Occasionally, e.g <a href="https://www.thrillist.com/entertainment/nation/is-rami-malek-singing-in-bohemian-rhapsody-freddie-mercury-voice">Rami Malek&#39;s portrayal of Freddie Mercury</a> In “Bohemian Rhapsody,” the actors lip-synch their very own voices and merge them with that of the singer they&#8217;re playing. </p>
<p>But directors let some actors imitate their very own voice.  Renée Zellweger sang as Judy Garland in “<a href="https://www.imdb.com/title/tt7549996/?ref_=nv_sr_srsg_8_tt_1_nm_7_q_judy">Judy</a>“Austin Butler <a href="https://www.esquire.com/entertainment/movies/a40392054/austin-butler-singing-elvis/">sang Elvis&#39; earlier songs himself</a> In &#8220;<a href="https://screenrant.com/did-austin-butler-sing-elvis-movie-songs/">Elvis</a>.” Like her, Marisa Abela also worked closely with a singing teacher.</p>
<p>Coaches reject the suggestion that actors do low cost impressions or imitations. </p>
<p>Eric Vetro, who worked with Timothée Chalamet for the upcoming Bob Dylan biopic &#8220;<a href="https://www.imdb.com/title/tt11563598/">An entire unknown</a>,, <a href="https://ew.com/movies/timothee-chalamet-bob-dylan-biopic-voice-not-impersonation-vocal-coach/">said Entertainment Weekly</a> that Chalamet &#8220;takes all of the characteristics of Dylan&#39;s voice, his mannerisms and his speech patterns and brings them into the music &#8211; in order that while you hear Timothée play the music, you actually get that Bob Dylan.&#8221;</p>
<p>Likewise Anne-Marie Speed, who trained Abela, <a href="https://www.rollingstone.com/tv-movies/tv-movie-news/marisa-abela-trained-like-an-athlete-amy-winehouse-biopic-1234947185/">said Rolling Stone</a>&#8220;You wish to [the vocal performance] be very close, but make no impression.” </p>
<figure class="align-center ">
<div class="placeholder-container" style="--aspect-ratio-percent:71.22015915119363%;--background-color:#9d585b"><img decoding="async" alt="Young man with shaggy curly hair wearing sunglasses and smoking a cigarette, looking out of a car window." class="lazyload" src="https://images.theconversation.com/files/593480/original/file-20240511-16-aeg1gi.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;fit=clip" srcset="https://images.theconversation.com/files/593480/original/file-20240511-16-aeg1gi.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=600&#038;h=427&#038;fit=crop&#038;dpr=1 600w, https://images.theconversation.com/files/593480/original/file-20240511-16-aeg1gi.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=600&#038;h=427&#038;fit=crop&#038;dpr=2 1200w, https://images.theconversation.com/files/593480/original/file-20240511-16-aeg1gi.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=600&#038;h=427&#038;fit=crop&#038;dpr=3 1800w, https://images.theconversation.com/files/593480/original/file-20240511-16-aeg1gi.jpg?ixlib=rb-4.1.0&#038;q=45&#038;auto=format&#038;w=754&#038;h=537&#038;fit=crop&#038;dpr=1 754w, https://images.theconversation.com/files/593480/original/file-20240511-16-aeg1gi.jpg?ixlib=rb-4.1.0&#038;q=30&#038;auto=format&#038;w=754&#038;h=537&#038;fit=crop&#038;dpr=2 1508w, https://images.theconversation.com/files/593480/original/file-20240511-16-aeg1gi.jpg?ixlib=rb-4.1.0&#038;q=15&#038;auto=format&#038;w=754&#038;h=537&#038;fit=crop&#038;dpr=3 2262w" sizes="(min-width: 1466px) 754px, (max-width: 599px) 100vw, (min-width: 600px) 600px, 237px"></div><figcaption>
              <span class="caption">Actor Timothée Chalamet on location for the Bob Dylan biography “A Complete Unknown” in New York City.</span><br />
              <span class="attribution"><a class="source" href="https://www.gettyimages.com/detail/news-photo/timothee-chalamet-is-seen-on-location-for-the-bob-dylan-news-photo/2110850824?adppopup=true">Gotham/GC images via Getty Images</a></span><br />
            </figcaption></figure>
<h2>Impressionism, not replication</h2>
<p>Actors who succeed at playing dead singers actually engage within the art of impersonation, very like the hordes of Elvis impersonators in Las Vegas.  The audience knows they aren&#8217;t seeing the actual person.  However, you wish the actors to acknowledge the artist&#39;s singing style, mannerisms and aura. </p>
<p>Ten years ago, <a href="https://books.google.com/books?hl=en&#038;lr=&#038;id=ctqUDwAAQBAJ&#038;oi=fnd&#038;pg=PA77&#038;dq=fluid+voices+meizel&#038;ots=88DIyrZkHr&#038;sig=WfZXUsvp1mGR1GxvmTpU7MUpseY#v=onepage&#038;q=fluid%20voices%20meizel&#038;f=false">I researched with vocal scientist Ron Scherer</a> to seek out out what was occurring when one singer tried to sound like one other. </p>
<p>I interviewed and recorded Canadian singer Véronic DiCaire before a performance at her Vegas impersonation show.<a href="https://www.youtube.com/watch?v=z9APz2kplmg">50 votes</a>.” She covered a variety of singers in her impressive repertoire: Adele, Whitney Houston and even Amy Winehouse. </p>
<p>When impersonating Tina Turner <a href="https://books.google.com/books?hl=en&#038;lr=&#038;id=btnBDwAAQBAJ&#038;oi=fnd&#038;pg=PA71&#038;dq=multivocality+meizel+celine&#038;ots=boq9bkgZLH&#038;sig=QWFyDewMHh9Ft3DoRleSVSZMQ8Q#v=onepage&#038;q=multivocality%20meizel%20celine&#038;f=false">DiCaire told me</a> that she needed very high heels to mimic Turner&#39;s posture.  When she impersonated other singers, she adjusted the a part of her vocal tract where she felt vibrations.  For Céline Dion, she explained how she originally desired to locate the voice in her nose.  But her teacher also identified that Dion “sings with that long neck.”  Their imitation subsequently required a combination of adjustments in posture and vocal technique. </p>
<p>Based on the photos I took, <a href="https://books.google.com/books?hl=en&#038;lr=&#038;id=ctqUDwAAQBAJ&#038;oi=fnd&#038;pg=PA77&#038;dq=meizel+fluid+voices&#038;ots=88DJysZqHo&#038;sig=Cef5tBUrrDqtXjxy_ILC2lTtF-E#v=onepage&#038;q=meizel%20fluid%20voices&#038;f=false">Scherer and I compared</a> <a href="https://emastered.com/blog/what-is-spectrogram">Spectrographic images</a> &#8211; Representations of the acoustic structure of a sound in diagram form &#8211; of DiCaire&#39;s own voice together with her imitations.  We then compared their imitations with spectrographic images from the unique artists.</p>
<p>We discovered that DiCaire didn&#8217;t produce exact replicas of the unique vocals she covered.  But she hit certain highlights of her vocal sounds, just like the pronunciation of certain vowels or consonants.  She also adjusted the frequency of her vibrato — and reshaped her vocal tract — to bring her timbre closer to that of Adele or Lady Gaga at key points in a song.</p>
<p><a href="https://www.indiewire.com/criticism/movies/back-to-black-review-amy-winehouse-biopic-1234972822/">A mixed review</a> of the film &#8220;Back to Black&#8221; criticizes it as &#8220;a crude highlight reel&#8221; of Winehouse&#39;s profession, although the writer praises Abela&#39;s &#8220;good impression of the late singer.&#8221;</p>
<p>But our research suggests that singing imitation is just that: a highlight reel. </p>
<p>In an Impressionist painting, the image lies within the artist&#39;s arrangement of many details which might be best viewed from a distance.  If you look too closely, all the pieces falls apart.</p>
</p></div>
<p><em>image credit : theconversation.com</em></p>
]]></content:encoded>
					
					<wfw:commentRss>https://bloggingthree.soflytech.com/2024/05/by-not-lip-syncing-amy-winehouses-songs-actress-marisa-abela-faces-unattainable-expectations-in-back-to-black/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<media:content url="https://i3.wp.com/images.theconversation.com/files/593479/original/file-20240511-16-kjxn2d.jpg" medium="image"></media:content>
				</item>
	</channel>
</rss>
